JENNIFER RAMSAY

Dr. JENNIFER RAMSAY


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2011 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
JRJasim M Radhi
Jasim M Radhi
JRJENNIFER RAMSAY
JENNIFER RAMSAY
OBOdette Boutross-Tadross
Odette Boutross-Tadross
The incidence of colonic diverticular disease varies with national origin, cultural background and diet. The frequency of this disease increases with advancing age. Right-sided diverticular disease is uncommon and reported to occur in 1-2% of surgical specimens in European and American series. In contrast the disease is more prevalent and reported in 43-50% of specimens in Asian series. Various lines of evidence suggest this variation may represent hereditary differences. The aim of the study is to report all cases of right sided diverticular disease underwent surgical resection or identified during pathological examination of right hemicoloectomy specimens

27 April 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
SCSze Wah Samuel Chan
Sze Wah Samuel Chan
RSRahul Shukla
Rahul Shukla
JRJENNIFER RAMSAY
JENNIFER RAMSAY
EMElaine McWhirter
Elaine McWhirter
PBPaul Barnfield
Paul Barnfield
RJRosalyn Anne Juergens
Rosalyn Anne Juergens
Background: Immune checkpoint inhibitors (ICI) are increasingly the mainstay of oncology treatment. Immune-related adverse events (irAEs) from ICI therapy differ from cytotoxic adverse events. Cutaneous irAEs are one of the most common irAEs and require careful attention to optimize the quality of life for oncology patients. Patient and Methods: These are two cases of patients with advanced solid-tumour malignancies treated with PD-1 inhibitor therapy. Results: Both patients developed multiple pruritic hyperkeratotic lesions, which were initially diagnosed as squamous cell carcinoma from skin biopsies. The presentation as squamous cell carcinoma was atypical and, upon further pathology review, the lesions were more in keeping with a lichenoid immune reaction stemming from the immune checkpoint blockade. With the use of oral or topical steroids and immunomodulators, the lesions resolved. Conclusions: These cases emphasize that patients on PD-1 inhibitor therapy who develop lesions resembling squamous cell carcinoma on initial pathology may require an additional pathology review to assess for immune-mediated reactions, allowing appropriate immunosuppressive therapy to be initiated.